Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Hofseth Biocare ASA ( (HOFBF) ) has provided an update.
Hofseth BioCare ASA has appointed Paul Bruhn as Head of New Business Development, leveraging his extensive experience in healthcare and medical nutrition to drive growth, particularly in Asia and the ANZ region. Bruhn’s expertise aligns with HBC’s innovative bioactive ingredients, which are poised to differentiate in the market by addressing clinical nutrition needs and supporting health with sustainable, scientifically backed products.
More about Hofseth Biocare ASA
Hofseth BioCare ASA is a Norwegian company focused on consumer and pet health, emphasizing sustainability and optimal use of natural resources. It transforms salmon industry by-products into health-improving ingredients like ProGo®, OmeGo®, and CalGo®, which offer various health benefits backed by scientific evidence. The company is also involved in biotech through its spin-off, HBC Immunology, targeting cancer and asthma therapies.
Average Trading Volume: 99,486
Current Market Cap: NOK731.7M
Find detailed analytics on HOFBF stock on TipRanks’ Stock Analysis page.